109 related articles for article (PubMed ID: 17264770)
1. Proceedings of the First International Conference on PEP005.
Ogbourne SM; Hampson P; Lord JM; Parsons P; De Witte PA; Suhrbier A
Anticancer Drugs; 2007 Mar; 18(3):357-62. PubMed ID: 17264770
[TBL] [Abstract][Full Text] [Related]
2. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
[TBL] [Abstract][Full Text] [Related]
3. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC.
Hampson P; Chahal H; Khanim F; Hayden R; Mulder A; Assi LK; Bunce CM; Lord JM
Blood; 2005 Aug; 106(4):1362-8. PubMed ID: 15845901
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death.
Ogbourne SM; Suhrbier A; Jones B; Cozzi SJ; Boyle GM; Morris M; McAlpine D; Johns J; Scott TM; Sutherland KP; Gardner JM; Le TT; Lenarczyk A; Aylward JH; Parsons PG
Cancer Res; 2004 Apr; 64(8):2833-9. PubMed ID: 15087400
[TBL] [Abstract][Full Text] [Related]
5. Ingenol mebutate: an introduction.
Fallen RS; Gooderham M
Skin Therapy Lett; 2012 Feb; 17(2):1-3. PubMed ID: 22358305
[TBL] [Abstract][Full Text] [Related]
6. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate.
Challacombe JM; Suhrbier A; Parsons PG; Jones B; Hampson P; Kavanagh D; Rainger GE; Morris M; Lord JM; Le TT; Hoang-Le D; Ogbourne SM
J Immunol; 2006 Dec; 177(11):8123-32. PubMed ID: 17114487
[TBL] [Abstract][Full Text] [Related]
7. The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.
Li L; Shukla S; Lee A; Garfield SH; Maloney DJ; Ambudkar SV; Yuspa SH
Cancer Res; 2010 Jun; 70(11):4509-19. PubMed ID: 20460505
[TBL] [Abstract][Full Text] [Related]
8. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.
Gupta AK; Paquet M
J Cutan Med Surg; 2013; 17(3):173-9. PubMed ID: 23673300
[TBL] [Abstract][Full Text] [Related]
9. The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers.
Ramsay JR; Suhrbier A; Aylward JH; Ogbourne S; Cozzi SJ; Poulsen MG; Baumann KC; Welburn P; Redlich GL; Parsons PG
Br J Dermatol; 2011 Mar; 164(3):633-6. PubMed ID: 21375515
[TBL] [Abstract][Full Text] [Related]
10. Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Anticancer Agents Med Chem; 2017; 17(10):1304-1311. PubMed ID: 28270072
[TBL] [Abstract][Full Text] [Related]
11. Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies.
Le TT; Gardner J; Hoang-Le D; Schmidt CW; MacDonald KP; Lambley E; Schroder WA; Ogbourne SM; Suhrbier A
Vaccine; 2009 May; 27(23):3053-62. PubMed ID: 19428919
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
[TBL] [Abstract][Full Text] [Related]
13. Ingenol mebutate: from common weed to cancer cure.
Zarchi K; Jemec GB
Curr Probl Dermatol; 2015; 46():136-42. PubMed ID: 25561218
[TBL] [Abstract][Full Text] [Related]
14. Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer.
Erlendsson AM
Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115209
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.
Benhadji KA; Serova M; Ghoul A; Cvitkovic E; Le Tourneau C; Ogbourne SM; Lokiec F; Calvo F; Hammel P; Faivre S; Raymond E
Br J Cancer; 2008 Dec; 99(11):1808-15. PubMed ID: 19034280
[TBL] [Abstract][Full Text] [Related]
16. The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity.
Ersvaer E; Kittang AO; Hampson P; Sand K; Gjertsen BT; Lord JM; Bruserud O
Toxins (Basel); 2010 Jan; 2(1):174-94. PubMed ID: 22069553
[TBL] [Abstract][Full Text] [Related]
17. Ingenol mebutate: a new option for actinic keratosis treatment.
Gras J
Drugs Today (Barc); 2013 Jan; 49(1):15-22. PubMed ID: 23362492
[TBL] [Abstract][Full Text] [Related]
18. Dermoscopic monitoring of efficacy of ingenol mebutate in the treatment of pigmented and non-pigmented basal cell carcinomas.
Diluvio L; Bavetta M; Di Prete M; Orlandi A; Bianchi L; Campione E
Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27860083
[TBL] [Abstract][Full Text] [Related]
19. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial.
Siller G; Rosen R; Freeman M; Welburn P; Katsamas J; Ogbourne SM
Australas J Dermatol; 2010 May; 51(2):99-105. PubMed ID: 20546215
[TBL] [Abstract][Full Text] [Related]
20. Unusual ingenoids from Euphorbia erythradenia Bioss. with pro-apoptotic effects.
Zarei SM; Ayatollahi AM; Ghanadian M; Kobarfard F; Aghaei M; Choudhary MI; Fallahian F
Fitoterapia; 2013 Dec; 91():87-94. PubMed ID: 23994233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
